Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture

Core Insights - Hemostemix Inc. has successfully closed the sale of 15 ACP-01 Therapy Convertible Debentures, raising proceeds of USD $517,230, pending TSXV Exchange approval [1][2] - The CEO of Hemostemix, Thomas Smeenk, emphasized that the approval of the Therapy Convertible Debenture (TCD) marks a significant advancement for the company, allowing for the sale of VesCell therapy to clinics, investors, and high net worth individuals [2] - The TCD is designed to streamline production and treatment schedules, enabling rapid scaling without diluting shareholder equity, positioning Hemostemix as a leader in autologous stem cell therapy for cardiovascular diseases [2] Company Overview - Hemostemix is an autologous stem cell therapy company founded in 2003, recognized as a World Economic Forum Technology Pioneer [5] - The company has treated 498 patients and completed seven clinical studies involving 318 subjects, with results published in nine peer-reviewed publications [5] - Hemostemix's ACP-01 therapy is clinically relevant and statistically significant for various cardiovascular conditions, including peripheral arterial disease and chronic limb threatening ischemia [5] Financial Details - Each TCD is convertible into an ACP-01 therapy and can be converted into common shares at a price of $0.155 per share, with an interest rate of 6% per annum payable in shares [3] - The proceeds from the TCD will be allocated for general working capital, corporate overhead, and research and development activities [4] - The company paid CA$59,171 and issued 356,298 Finder's Warrants to a finder in connection with the TCD offering, allowing the purchase of common shares at $0.155 per share [4]